{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:30:05Z","timestamp":1792985405261,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100022572","name":"NIHR Sheffield Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004876","name":"Sheffield Hospitals Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.nmd.2026.106470","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:17:58Z","timestamp":1781223478000},"page":"106470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6175-7027","authenticated-orcid":false,"given":"Channa","family":"Hewamadduma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-7063","authenticated-orcid":false,"given":"Jon","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Weatherley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol C.","family":"Voermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5999","key":"10.1016\/j.nmd.2026.106470_bib0001","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0002","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0003","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1399-0004.2009.01158.x","article-title":"Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample","volume":"75","author":"Mostacciuolo","year":"2009","journal-title":"Clin Genet"},{"issue":"9","key":"10.1016\/j.nmd.2026.106470_bib0004","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1007\/s10072-025-08276-7","article-title":"Describing phenotypes in FSHD: an update of the comprehensive clinical evaluation form","volume":"46","author":"Ricci","year":"2025","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/mus.26474","article-title":"Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy","volume":"59","author":"Ricci","year":"2019","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0006","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/CON.0000000000000399","article-title":"Facioscapulohumeral muscular dystrophy","volume":"22","author":"Statland","year":"2016","journal-title":"CONTIN: Lifelong Learn Neurol"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0007","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1212\/WNL.0000000000008123","article-title":"Patient-reported symptoms in facioscapulohumeral muscular dystrophy (PRISM-FSHD)","volume":"93","author":"Hamel","year":"2019","journal-title":"Neurology"},{"issue":"Preprint","key":"10.1016\/j.nmd.2026.106470_bib0008","first-page":"1","article-title":"Facioscapulohumeral muscular dystrophy European patient survey: assessing patient reported disease burden and preferences in clinical trial participation","author":"McNiff","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0009","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.nmd.2013.01.008","article-title":"Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy","volume":"23","author":"Statland","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0010","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/mus.23529","article-title":"Patient-identified disease burden in facioscapulohumeral muscular dystrophy","volume":"46","author":"Johnson","year":"2012","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000095137","article-title":"Influence of relatives on fatigue experienced by patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I","volume":"56","author":"Kalkman","year":"2006","journal-title":"Eur Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0012","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/jpm12060865","article-title":"FSHD therapeutic strategies: what will it take to get to clinic?","volume":"12","author":"Himeda","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.nmd.2026.106470_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/22143602261419558","article-title":"A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: results of the REACH study","author":"Voermans","year":"2026","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/WCO.0000000000001176","article-title":"The FSHD jigsaw: are we placing the tiles in the right position?","volume":"36","author":"Salsi","year":"2023","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad221","article-title":"The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy","volume":"5","author":"Banerji","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2026.106470_bib0016","article-title":"Meeting report: the FSHD society 2025 international research congress","author":"Ronco","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0017","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00415-016-8361-3","article-title":"MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients","volume":"264","author":"Andersen","year":"2017","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/WNL.48.1.38","article-title":"A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials","volume":"48","year":"1997","journal-title":"Neurology"},{"issue":"18 SUPPL","key":"10.1016\/j.nmd.2026.106470_bib0019","article-title":"Whole body MRI quantitative muscle analysis to evaluate efficacy of Losmapimod in a phase 2 placebo-controlled study in subjects with FSHD (ReDUX4)","volume":"98","author":"Mellion","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12891-021-04134-7","article-title":"Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.nmd.2026.106470_bib0021","first-page":"30","article-title":"Facioscapulohumeral muscular dystrophy functional composite outcome measure","volume":"30","author":"Eichinger","year":"2018","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.nmd.2026.106470_bib0022","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/ene.14863","article-title":"The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS)","volume":"28","author":"Mul","year":"2021","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.27951","article-title":"The facioscapulohumeral muscular dystrophy-health index: development and evaluation of a disease-specific outcome measure","volume":"68","author":"Varma","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0024","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12883-019-1452-x","article-title":"Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study","volume":"19","author":"LoRusso","year":"2019","journal-title":"BMC Neurol"},{"issue":"18_supplement","key":"10.1016\/j.nmd.2026.106470_bib0025","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.98.18_supplement.1479","article-title":"Motor outcomes to validate evaluations in facioscapulohumeral muscular dystrophy (MOVE FSHD): protocol for an observational study.(S29. 007)","volume":"98","author":"Walker","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106470_bib0026","series-title":"2026 AAN Annual Meeting","article-title":"Current abilities score (CAS) is a valid and a reliable PROM in FSHD: data from MOVE natural history study","author":"Hewamadduma","year":"2026"},{"issue":"11","key":"10.1016\/j.nmd.2026.106470_bib0027","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.nmd.2019.09.003","article-title":"Measurement properties and utility of performance-based outcome measures of physical functioning in individuals with facioscapulohumeral dystrophy - a systematic review and evidence synthesis","volume":"29","author":"de Valle","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0028","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cells11040687","article-title":"Outcome measures in facioscapulohumeral muscular dystrophy clinical trials","volume":"11","author":"Ghasemi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.nmd.2026.106470_bib0029","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-026-02519-7","article-title":"Measuring health-related quality of life in facioscapulohumeral muscular dystrophy: a COSMIN systematic review and conceptual framework","volume":"24","author":"Carlton","year":"2026","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2026.106470_bib0030","series-title":"149 Health-related quality of life: results from a large FSHD patient survey, and clinical assessments","author":"Street","year":"2025"},{"issue":"Suppl 6","key":"10.1016\/j.nmd.2026.106470_bib0031","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12911-021-01534-6","article-title":"ICD-11: an international classification of diseases for the twenty-first century","volume":"21","author":"Harrison","year":"2021","journal-title":"BMC Med Inf Decis Mak"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0032","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0033","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1452-x","article-title":"Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study","volume":"19","author":"LoRusso","year":"2019","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ptj\/74.3.253","article-title":"Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group","volume":"74","author":"Personius","year":"1994","journal-title":"Phys Ther"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0036","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.28293","article-title":"A 5-year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials","volume":"71","author":"Kools","year":"2025","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0037","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.nmd.2023.10.020","article-title":"The Dutch registry for facioscapulohumeral muscular dystrophy: cohort profile and longitudinal patient reported outcomes","volume":"33","author":"Kools","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0038","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01793-6","article-title":"Convergence of patient- and physician-reported outcomes in the French National registry of facioscapulohumeral dystrophy","volume":"17","author":"Sanson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2026.106470_bib0039","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00415-016-8132-1","article-title":"Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry","volume":"263","author":"Evangelista","year":"2016","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.25251","article-title":"Validity of the 6 min walk test in facioscapulohumeral muscular dystrophy","volume":"55","author":"Eichinger","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.27558","article-title":"Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy","volume":"66","author":"Statland","year":"2022","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0042","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mus.28031","article-title":"A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD)","volume":"69","author":"Varma","year":"2024","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0043","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200292","article-title":"Study of testosterone and recombinant Human growth hormone in facioscapulohumeral muscular dystrophy","volume":"11","author":"Heatwole","year":"2025","journal-title":"Neurol Genet"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0044","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.apmr.2015.08.429","article-title":"Clinical functional capacity testing in patients with facioscapulohumeral muscular dystrophy: construct validity and interrater reliability of antigravity tests","volume":"96","author":"Rijken","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mus.24569","article-title":"Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy","volume":"52","author":"Leung","year":"2015","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.nmd.2026.106470_bib0046","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0047","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/01.WNL.0000134660.30793.1F","article-title":"Strength training and albuterol in facioscapulohumeral muscular dystrophy","volume":"63","author":"Van Der Kooi","year":"2004","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.nmd.2026.106470_bib0048","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/01.wnl.0000264017.08217.39","article-title":"Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy","volume":"68","author":"Elsheikh","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0049","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2026.106470_bib0050","first-page":"169","article-title":"Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses","volume":"49","author":"Aprile","year":"2013","journal-title":"Eur J Phys Rehabil Med"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0051","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/16501977-2222","article-title":"Reliability of the 2-and 6-minute walk tests in neuromuscular diseases","volume":"49","author":"Knak","year":"2017","journal-title":"J Rehabil Med"},{"issue":"8","key":"10.1016\/j.nmd.2026.106470_bib0052","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0053","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/01.WNL.0000134660.30793.1F","article-title":"Strength training and albuterol in facioscapulohumeral muscular dystrophy","volume":"63","author":"van der Kooi","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0054","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MRR.0000000000000614","article-title":"Fitness and walking outcomes following aerobic and lower extremity strength training in facioscapulohumeral dystrophy: a case series","volume":"47","author":"Prieur-Blanc","year":"2024","journal-title":"Int J Rehabil Res"},{"issue":"2","key":"10.1016\/j.nmd.2026.106470_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mus.21671","article-title":"A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: the FSHD clinical score","volume":"42","author":"Lamperti","year":"2010","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0056","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.nmd.2023.10.015","article-title":"Establishing the role of muscle ultrasound as an imaging biomarker in facioscapulohumeral muscular dystrophy","volume":"33","author":"Vincenten","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.nmd.2026.106470_bib0057","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/hmg\/ddae007","article-title":"Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression","volume":"33","author":"Wong","year":"2024","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106470_bib0058","first-page":"07","article-title":"Interleukin-6 as a key biomarker in facioscapulohumeral dystrophy: evidence from longitudinal analyses","volume":"07","author":"Pini","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2026.106470_bib0059","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70238","article-title":"The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS): longitudinal assessment of a disease-specific patient reported outcome","volume":"32","author":"Teeselink","year":"2025","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2026.106470_bib0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure scale for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"20","key":"10.1016\/j.nmd.2026.106470_bib0061","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","article-title":"Adding quantitative muscle MRI to the FSHD clinical trial toolbox","volume":"89","author":"Mul","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.nmd.2026.106470_bib0062","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1007\/s00415-018-9037-y","article-title":"Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers","volume":"265","author":"Mul","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0063","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MRR.0000000000000444","article-title":"Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy","volume":"44","author":"Mul","year":"2021","journal-title":"Int J Rehabil Res"},{"issue":"8","key":"10.1016\/j.nmd.2026.106470_bib0064","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.nmd.2021.05.011","article-title":"Reliability and validity of the FSHD-composite outcome measure in childhood facioscapulohumeral dystrophy","volume":"31","author":"de Valle","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0065","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/jcsm.13250","article-title":"Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: the link to clinical outcome","volume":"14","author":"Vincenten","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nmd.2026.106470_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.735936","article-title":"Consensus guidelines for improving quality of assessment and training for neuromuscular diseases","volume":"12","author":"Duong","year":"2021","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.nmd.2026.106470_bib0067","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/mus.24287","article-title":"Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect","volume":"51","author":"Han","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106470_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105279","article-title":"Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophy","volume":"48","author":"Wang","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nmd.2026.106470_bib0069","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.27123","article-title":"Motion sensor-acquired reachable workspace correlates with patient-reported upper extremity activities of daily living (ADL) function in facioscapulohumeral dystrophy","volume":"63","author":"Hatch","year":"2021","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.nmd.2026.106470_bib0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nmd.2019.05.006","article-title":"Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy","volume":"29","author":"Hatch","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106470_bib0071","author":"Therapeutics"},{"issue":"14","key":"10.1016\/j.nmd.2026.106470_bib0072","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.3390\/s23146563","article-title":"A single-sensor approach to quantify gait in patients with hereditary spastic Paraplegia","volume":"23","author":"van Gelder","year":"2023","journal-title":"Sensors"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0073","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050785","article-title":"Technical validation of real-world monitoring of gait: a multicentric observational study","volume":"11","author":"Mazz\u00e0","year":"2021","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.nmd.2026.106470_bib0074","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00415-020-09928-8","article-title":"Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting","volume":"267","author":"Angelini","year":"2020","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-023-02813-3","article-title":"The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review","volume":"18","author":"Poleur","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0076","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/mus.25955","article-title":"An instrumented timed up and go in facioscapulohumeral muscular dystrophy","volume":"57","author":"Huisinga","year":"2018","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0077","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/mus.26681","article-title":"A pilot study of the responsiveness of wireless motion analysis in facioscapulohumeral muscular dystrophy","volume":"60","author":"Statland","year":"2019","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.nmd.2026.106470_bib0078","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/jnnp.2009.173534","article-title":"Epidemiology and pathophysiology of falls in facioscapulohumeral disease","volume":"80","author":"Horlings","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0079","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jcsm.12473","article-title":"Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging","volume":"10","author":"Monforte","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.27074","article-title":"Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy","volume":"63","author":"Lassche","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106470_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.rehab.2014.03.329","article-title":"Both aerobic exercise training and cognitive behavior therapy reduce chronic fatigue in patients with facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"57","author":"Voet","year":"2014","journal-title":"Ann Phys Rehabil Med"},{"issue":"9","key":"10.1016\/j.nmd.2026.106470_bib0082","doi-asserted-by":"crossref","DOI":"10.1056\/AIoa2401137","article-title":"Video-based biomechanical analysis captures disease-specific movement signatures of different neuromuscular diseases","volume":"2","author":"Ruth","year":"2025","journal-title":"Nejm Ai"},{"issue":"3","key":"10.1016\/j.nmd.2026.106470_bib0083","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.nmd.2017.11.017","article-title":"Specific muscle strength is reduced in facioscapulohumeral dystrophy: an MRI based musculoskeletal analysis","volume":"28","author":"Marra","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0084","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.50.5.1402","article-title":"Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"50","author":"Kissel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106470_bib0085","first-page":"20","article-title":"Multi-scale machine learning model predicts muscle and functional disease progression in FSHD","volume":"20","author":"Blemker","year":"2025","journal-title":"BioRxiv : Prepr Serv Biol"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0086","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mus.27527","article-title":"Explanatory factors of dynamic balance impairment in myotonic dystrophy type 1","volume":"65","author":"B\u00e9lair","year":"2022","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0087","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00415-025-13062-8","article-title":"Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRI: a prospective cohort study","volume":"272","author":"Paoletti","year":"2025","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0088","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mus.70002","article-title":"Reliability and validity of the reachable workspace total score with wrist weight in facioscapulohumeral muscular dystrophy","volume":"72","author":"Hubig","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106470_bib0089","series-title":"151 Muscle strength assessment in clinic using handheld dynamometry in FSHD-is it feasible and valid?:","author":"Street","year":"2025"},{"key":"10.1016\/j.nmd.2026.106470_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123096","article-title":"An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1","volume":"462","author":"Kools","year":"2024","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.nmd.2026.106470_bib0091","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/jcsm.12347","article-title":"Relationships between muscle size, strength, and physical activity in adults with muscular dystrophy","volume":"9","author":"Jacques","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.nmd.2026.106470_bib0092","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","article-title":"Development of the P erformance of the U pper L imb module for D uchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2026.106470_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.454","article-title":"194P Longitudinal assessment of the Adapted Test for Neuromuscular Disease (ATEND) in individuals living with spinal muscular atrophy (SMA)","volume":"43","author":"Duong","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0094","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210059","article-title":"Longitudinal insights into childhood onset facioscapulohumeral dystrophy: a 5-year natural history study","volume":"104","author":"Dijkstra","year":"2025","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.nmd.2026.106470_bib0095","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.25326","article-title":"Facioscapulohumeral dystrophy in childhood: a nationwide natural history study","volume":"84","author":"Goselink","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2026.106470_bib0096","author":"Dijkstra","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2026.106470_bib0097","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1590\/0004-282x-anp-2021-0034","article-title":"Speech and swallowing characteristics in patients with facioscapulohumeral muscular dystrophy","volume":"80","author":"Dos Santos","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"10.1016\/j.nmd.2026.106470_bib0098","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1212\/WNL.0000000000007013","article-title":"Effects of weakness of orofacial muscles on swallowing and communication in FSHD","volume":"92","author":"Mul","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106470_bib0099","article-title":"Assessing disease progression in spinal muscular atrophy, current gaps, and opportunities: a narrative review","author":"Muni-Lofra","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2026.106470_bib0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00019053-200624010-00004","article-title":"Incorporating carer effects into economic evaluation","volume":"24","author":"Dixon","year":"2006","journal-title":"Pharmacoeconomics"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:36:20Z","timestamp":1785911780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"alternative-id":["S0960896626001380"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106470","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106470"}}